Does the media refer more to TARS or CYTK?

In the previous week, Cytokinetics had 5 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 9 mentions for Cytokinetics and 4 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.64 beat Cytokinetics' score of -0.04 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer KRYS or TARS?

In the previous week, Krystal Biotech had 1 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 5 mentions for Krystal Biotech and 4 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.64 beat Krystal Biotech's score of 0.31 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tarsus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NUVL or TARS?

In the previous week, Nuvalent had 4 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 8 mentions for Nuvalent and 4 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.64 beat Nuvalent's score of 0.03 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Tarsus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TARS or IBRX?

In the previous week, ImmunityBio had 4 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 8 mentions for ImmunityBio and 4 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.64 beat ImmunityBio's score of -0.09 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Tarsus Pharmaceuticals (TARS) Competitors

$59.28 -1.06 (-1.76%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$58.50 -0.77 (-1.31%)

As of 06/5/2026 05:00 PM Eastern

Compare

TARS vs. PRAX, CYTK, KRYS, NUVL, and IBRX

Should you buy Tarsus Pharmaceuticals stock or one of its competitors? MarketBeat compares Tarsus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tarsus Pharmaceuticals include Praxis Precision Medicines (PRAX), Cytokinetics (CYTK), Krystal Biotech (KRYS), Nuvalent (NUVL), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does Tarsus Pharmaceuticals compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Praxis Precision Medicines has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

Praxis Precision Medicines presently has a consensus price target of $572.72, indicating a potential upside of 125.48%. Tarsus Pharmaceuticals has a consensus price target of $90.67, indicating a potential upside of 52.95%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Tarsus Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	828.25	-$303.27M	-$13.37	N/A
Tarsus Pharmaceuticals	$451.36M	5.65	-$66.42M	-$1.14	N/A

Praxis Precision Medicines has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Praxis Precision Medicines had 22 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 4 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.64 beat Praxis Precision Medicines' score of -0.08 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Praxis Precision Medicines beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Cytokinetics?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Tarsus Pharmaceuticals has a net margin of -9.02% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Cytokinetics	-784.02%	N/A	-52.86%

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tarsus Pharmaceuticals has higher revenue and earnings than Cytokinetics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	5.65	-$66.42M	-$1.14	N/A
Cytokinetics	$88.04M	101.03	-$784.96M	-$6.84	N/A

In the previous week, Cytokinetics had 5 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 9 mentions for Cytokinetics and 4 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.64 beat Cytokinetics' score of -0.04 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tarsus Pharmaceuticals presently has a consensus price target of $90.67, indicating a potential upside of 52.95%. Cytokinetics has a consensus price target of $99.30, indicating a potential upside of 38.92%. Given Tarsus Pharmaceuticals' higher probable upside, equities research analysts clearly believe Tarsus Pharmaceuticals is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

Tarsus Pharmaceuticals has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

Summary

Tarsus Pharmaceuticals beats Cytokinetics on 10 of the 16 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Krystal Biotech currently has a consensus target price of $324.11, suggesting a potential upside of 7.68%. Tarsus Pharmaceuticals has a consensus target price of $90.67, suggesting a potential upside of 52.95%. Given Tarsus Pharmaceuticals' higher probable upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

In the previous week, Krystal Biotech had 1 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 5 mentions for Krystal Biotech and 4 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.64 beat Krystal Biotech's score of 0.31 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Krystal Biotech has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	22.80	$204.83M	$7.48	40.24
Tarsus Pharmaceuticals	$451.36M	5.65	-$66.42M	-$1.14	N/A

Krystal Biotech has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Krystal Biotech has a net margin of 53.92% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Krystal Biotech's return on equity of 19.25% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

Summary

Krystal Biotech beats Tarsus Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Nuvalent has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

In the previous week, Nuvalent had 4 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 8 mentions for Nuvalent and 4 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.64 beat Nuvalent's score of 0.03 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvalent presently has a consensus price target of $141.24, suggesting a potential upside of 55.29%. Tarsus Pharmaceuticals has a consensus price target of $90.67, suggesting a potential upside of 52.95%. Given Nuvalent's stronger consensus rating and higher possible upside, analysts clearly believe Nuvalent is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.94
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Nuvalent has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

Tarsus Pharmaceuticals has higher revenue and earnings than Nuvalent. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Tarsus Pharmaceuticals	$451.36M	5.65	-$66.42M	-$1.14	N/A

97.3% of Nuvalent shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 5.0% of Nuvalent shares are held by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Nuvalent and Tarsus Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to ImmunityBio?

Tarsus Pharmaceuticals (NASDAQ:TARS) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Tarsus Pharmaceuticals has a net margin of -9.02% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
ImmunityBio	-606.15%	N/A	-59.53%

In the previous week, ImmunityBio had 4 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 8 mentions for ImmunityBio and 4 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.64 beat ImmunityBio's score of -0.09 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Tarsus Pharmaceuticals has higher revenue and earnings than ImmunityBio. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	5.65	-$66.42M	-$1.14	N/A
ImmunityBio	$113.29M	63.97	-$351.40M	-$0.85	N/A

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 69.5% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tarsus Pharmaceuticals presently has a consensus price target of $90.67, indicating a potential upside of 52.95%. ImmunityBio has a consensus price target of $14.20, indicating a potential upside of 105.20%. Given ImmunityBio's higher probable upside, analysts plainly believe ImmunityBio is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Tarsus Pharmaceuticals has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its share price is 97% less volatile than the broader market.

Summary

Tarsus Pharmaceuticals beats ImmunityBio on 9 of the 17 factors compared between the two stocks.

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARS vs. The Competition

Export

Metric	Tarsus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.55B	$3.34B	$6.68B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.55%
P/E Ratio	-52.00	18.85	24.03	23.63
Price / Sales	5.65	300.34	519.33	112.45
Price / Cash	N/A	116.33	42.23	54.60
Price / Book	7.33	6.51	9.73	6.35
Net Income	-$66.42M	$24.19M	$3.57B	$337.59M
7 Day Performance	-0.20%	-6.96%	-1.27%	-2.52%
1 Month Performance	-7.32%	-2.80%	1.39%	-0.03%
1 Year Performance	34.97%	36.80%	23.95%	25.34%

Tarsus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TARS Tarsus Pharmaceuticals	3.1088 of 5 stars	$59.28 -1.8%	$90.67 +52.9%	+35.0%	$2.55B	$451.36M	N/A	50	Analyst Upgrade
PRAX Praxis Precision Medicines	2.855 of 5 stars	$290.75 -16.9%	$578.22 +98.9%	+470.0%	$9.34B	N/A	N/A	110	News Coverage Analyst Forecast Analyst Revision
CYTK Cytokinetics	2.8201 of 5 stars	$71.79 -6.5%	$99.30 +38.3%	+121.3%	$9.17B	$105.82M	N/A	250
KRYS Krystal Biotech	3.3441 of 5 stars	$293.18 -5.1%	$324.11 +10.6%	+119.8%	$9.11B	$417.30M	39.33	210	Insider Trade
NUVL Nuvalent	3.4695 of 5 stars	$90.38 -18.1%	$140.29 +55.2%	+16.6%	$8.72B	N/A	N/A	40	Analyst Forecast Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARS) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. PRAX, CYTK, KRYS, NUVL, and IBRX

How does Tarsus Pharmaceuticals compare to Praxis Precision Medicines?

Summary

How does Tarsus Pharmaceuticals compare to Cytokinetics?

Summary

How does Tarsus Pharmaceuticals compare to Krystal Biotech?

Summary

How does Tarsus Pharmaceuticals compare to Nuvalent?

Summary

How does Tarsus Pharmaceuticals compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. PRAX, CYTK, KRYS, NUVL, and IBRX

How does Tarsus Pharmaceuticals compare to Praxis Precision Medicines?

Which has more risk and volatility, PRAX or TARS?

Do analysts recommend PRAX or TARS?

Which has stronger valuation & earnings, PRAX or TARS?

Is PRAX or TARS more profitable?

Do insiders & institutionals have more ownership in PRAX or TARS?

Does the media prefer PRAX or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Cytokinetics?

Is TARS or CYTK more profitable?

Do insiders and institutionals have more ownership in TARS or CYTK?

Which has stronger valuation & earnings, TARS or CYTK?

Does the media refer more to TARS or CYTK?

Do analysts recommend TARS or CYTK?

Which has more volatility and risk, TARS or CYTK?

Summary

How does Tarsus Pharmaceuticals compare to Krystal Biotech?

Do analysts rate KRYS or TARS?

Does the media prefer KRYS or TARS?

Do insiders & institutionals believe in KRYS or TARS?

Which has higher valuation and earnings, KRYS or TARS?

Which has more volatility and risk, KRYS or TARS?

Is KRYS or TARS more profitable?

Summary

How does Tarsus Pharmaceuticals compare to Nuvalent?

Is NUVL or TARS more profitable?

Does the media favor NUVL or TARS?

Do analysts rate NUVL or TARS?

Which has more volatility & risk, NUVL or TARS?

Which has preferable earnings & valuation, NUVL or TARS?

Do insiders and institutionals believe in NUVL or TARS?

Summary

How does Tarsus Pharmaceuticals compare to ImmunityBio?

Is TARS or IBRX more profitable?

Does the media prefer TARS or IBRX?

Which has higher earnings and valuation, TARS or IBRX?

Do insiders & institutionals have more ownership in TARS or IBRX?

Do analysts recommend TARS or IBRX?

Which has more risk and volatility, TARS or IBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools